Test panel guides diagnosis of early onset IBD

Answers from the Lab

The incidence of inflammatory bowel disease, or IBD, has rapidly increased — especially among children. In this test-specific episode of the "Answers From the Lab" podcast, Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' gene sequencing panel (Test ID: EOIBD) comprehensively evaluates patients with suspected monogenic early onset IBD.

"The results can be game changers for these patients," Dr. Moyer says. "Testing can not only help establish the diagnosis but also guide therapy."

Monogenic IBD is caused by variance in a single gene. Mayo Clinic Laboratories' test panel covers 107 genes. It's designed to provide greater accuracy than alternative options, such as functional testing, or exome or genome sequencing.

"Our specialized team includes laboratory technologists, genetic counselors, and laboratory directors, who work together to interpret the results for each patient tested," Dr. Moyer says.

Listen to learn more about Mayo Clinic Laboratories' EOIBD test panel.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.


The latest

Barbara J. Toman

Barbara J. Toman is a Senior Communications Specialist at Mayo Clinic Laboratories. She is also the science writer for Mayo’s Neurosciences Update newsletter, which helps referring physicians to stay informed about Mayo’s treatment and research. Barbara has worked at Mayo Clinic since 2007. She enjoys international travel and cooking.